239 related articles for article (PubMed ID: 27911989)
1. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
Carson KR; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta MA; Shustov AR; Advani RH; Feldman TA; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
Cancer; 2017 Apr; 123(7):1174-1183. PubMed ID: 27911989
[TBL] [Abstract][Full Text] [Related]
2. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Shustov AR;
Cancer; 2019 May; 125(9):1507-1517. PubMed ID: 30694529
[TBL] [Abstract][Full Text] [Related]
3. Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database.
Bhatt VR; Giri S; Verma V; Manandhar S; Pathak R; Bociek RG; Vose JM; Armitage JO
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):373-8. PubMed ID: 27349764
[TBL] [Abstract][Full Text] [Related]
4. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
5. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
[TBL] [Abstract][Full Text] [Related]
6. Peripheral T-cell lymphoma--not otherwise specified.
Savage KJ; Ferreri AJ; Zinzani PL; Pileri SA
Crit Rev Oncol Hematol; 2011 Sep; 79(3):321-9. PubMed ID: 20702104
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
8. The aggressive peripheral T-cell lymphomas: 2015.
Armitage JO
Am J Hematol; 2015 Jul; 90(7):665-73. PubMed ID: 26031230
[TBL] [Abstract][Full Text] [Related]
9. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
[TBL] [Abstract][Full Text] [Related]
10. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
11. NOT OTHERWISE SPECIFIED T-CELL LYMPHOMA: OUTCOMES OF A SINGLE CENTER STUDY.
Kriachok I; Tytorenko I; Shudrak N; Aleksik O; Stepanishyna Y; Kadnikova T; Pastushenko Y; Shokun N; Rudiyk T; Bushuieva M
Exp Oncol; 2024 Feb; 45(4):474-482. PubMed ID: 38328842
[TBL] [Abstract][Full Text] [Related]
12. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management.
Armitage JO
Am J Hematol; 2012 May; 87(5):511-9. PubMed ID: 22508369
[TBL] [Abstract][Full Text] [Related]
13. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation.
Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J
Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868
[TBL] [Abstract][Full Text] [Related]
14. CHOP or THP-COP regimens in the treatment of newly diagnosed peripheral T-cell lymphoma, not otherwise specified: a comparison of doxorubicin and pirarubicin.
Shibata Y; Hara T; Kasahara S; Yamada T; Sawada M; Mabuchi R; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Kito Y; Goto N; Miyazaki T; Takami T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Jun; 35(2):163-171. PubMed ID: 26449182
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of l-kynurenine predict clinical outcomes of patients with peripheral T-cell lymphoma, not otherwise specified.
Shibata Y; Hara T; Matsumoto T; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Goto N; Nannya Y; Ito H; Kito Y; Miyazaki T; Takeuchi T; Saito K; Seishima M; Takami T; Moriwaki H; Shimizu M; Tsurumi H
Hematol Oncol; 2017 Dec; 35(4):637-644. PubMed ID: 27338762
[TBL] [Abstract][Full Text] [Related]
17. Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
Hsi ED; Horwitz SM; Carson KR; Pinter-Brown LC; Rosen ST; Pro B; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Collie AM; Gruver AM; Grzywacz BJ; Turakhia S; Shustov AR; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Lansigan F; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):193-200. PubMed ID: 28209473
[TBL] [Abstract][Full Text] [Related]
18. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.
Gordon MJ; Duan Z; Zhao H; Nastoupil L; Ng S; Danilov AV; Iyer S; Giordano SH
Leuk Lymphoma; 2023 Dec; 64(14):2258-2268. PubMed ID: 37706491
[TBL] [Abstract][Full Text] [Related]
19. How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
Schmitz N; de Leval L
Br J Haematol; 2017 Mar; 176(6):851-866. PubMed ID: 27982416
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
